The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections (uUTIs).

Key presentations at Eyecelerator in Chicago and AusBiotechInvest Conference PolyActiva is developing biodegradable ocular implants that provide ...

The Food and Drug Administration (FDA) has granted accelerated approval to Scemblix ® (asciminib) for the treatment of adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid ...

U.S. Food and Drug Administration (FDA) lifted Clinical Hold on COVALENT-111 (Type 2 Diabetes) & COVALENT-112 (Type 1 Diabetes) trialsCOVALENT-111 Phase 2b 26-week topline data of the dose expansion ...

A small tweak in the dosing regimen of Eli Lilly’s Alzheimer’s disease drug Kisunla has reduced brain swelling of patients in ...

The expanded indication in Ph+ CML-CP increases the population eligible for Scemblix by approximately four times, including newly diagnosed and previously treated adults. Newly diagnosed patients will ...

Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial ...

Longevity seekers are taking rapamycin in hopes of living longer. Here’s what a health and longevity doctor has to say about ...

26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric disorder ... and tended to lessen with time. The label also alerts patients that the drug is associated with ...

TreeHouse Foods, based in Oak Brook, Ill., is recalling all products manufactured at its facility in Brantford, Ontario, ...

The FDA granted an accelerated approval to asciminib for newly diagnosed Ph+ chronic myeloid leukemia in the chronic phase.

Asciminib has gained accelerated approval from the FDA for the treatment of patients with newly diagnosed Philadelphia ...